Select license type

Please Select Linenece Type

Key Benefits

  • Consult directly with our domain leaders and get expert advice regarding the upcoming market.
  • Get the latest market insights and forecasts backed up by powerful research and statistical analysis
  • Customize the report as per your requirements and area of focus to avail great benefits for your business.
Market Research Report

Global Self-Injectable Belimumab Market by Mode of Injection (Subcutaneous Autoinjector, Subcutaneous Prefilled Syringe, & Intravenous Infusion), by Geography, and Market Opportunity Assessment With Forecast 2016-2024

Published On : 2018-02-22 Report Page : 260 Category: Healthcare

Global Self-injectable Belimumab Market

Market Overview

The European Commission has rubber-stamped a brand new subcutaneous formulation of belimumab (Benlysta, GlaxoSmithKline) as adjunctive treatment for adults with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy. Systemic lupus erythematosus (SLE), a heterogeneous condition that significantly impact on morbidity and mortality among affected individuals, mainly young females during their most productive stage in life. The production of pathogenic autoantibodies has been the classical hallmark for the disease. B cells, the precursor of the antibody producing plasma cells, are believed to play a central role in SLE disease activity. It has long been considered a difficult disease to manage and diagnose due to its wide raging manifestations and severity.

Goldstein Research analyst forecast the Self-injectable Belimumab Market size is set to reach USD 7.2 million by 2024, at a CAGR of 8.7% over the forecast years.

Covered In This Global Self-injectable Belimumab Market Report           

The report covers the present ground scenario and the future growth prospects of the Self-injectable Belimumab Market for 2016-2024 along with its adoption rate worldwide. We calculated the market size and revenue share on the basis of revenue generated from major players across the globe.

Global Self-injectable Belimumab Market Segmentation

By Mode of Injection

  • Subcutaneous Autoinjector
  • Subcutaneous Prefilled Syringe
  • Intravenous Infusion

Based on Geography

  • North America (U.S. & Canada) Self-injectable Belimumab Market
  • Latin America (Brazil, Mexico, Argentina & Rest of Latin America) Self-injectable Belimumab Market
  • Europe (The U.K., Germany, France, Italy, Spain, Poland, Sweden & RoE) Self-injectable Belimumab Market
  • Asia-Pacific (China, India, Japan, Singapore, South Korea, Australia, New Zealand, Rest of Asia) Self-injectable Belimumab Market
  • Middle East & Africa (GCC, South Africa, North Africa, RoMEA) Self-injectable Belimumab Market

On the basis of mode of injection, subcutaneous autoinjector will be the leading segment in the forecast years due to its ease of usage and also the new self-injectable belimumab may improve quality of life for many people with lupus. For people living with a disease that too often necessitates multiple medications and numerous regular doctors’ visits, the convenience and independence offered by being able to take one treatment in the privacy and comfort of your own home can mean a great deal.

Self-injectable Belimumab Market Outlook 2016-2024, has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the global Self-injectable Belimumab market. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global Self-injectable Belimumab market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.

Our global Self-injectable Belimumab market report comprises of the following company as the key player in the Self-injectable Belimumab market: GSK.

According to our global market study on the basis of extensive primary and secondary research:  “One trend is it’s current approved as a one-hour intravenous infusion given once every four weeks by a healthcare professional in a hospital or clinic. The new formulation allows patients to administer the drug to themselves as a once-weekly injection for Systemic Lupus Erythematosus (SLE), which is the most common form of lupus, a chronic, incurable autoimmune disease producing autoantibodies that can attack almost any system in the body.”

According to the report, major driving factor for Self-injectable Belimumab market is the increasing prevalence of systemic lupus erythematosus, for instance, prevalence of systemic lupus erythematosus (SLE) in the United States is 20 to 150 cases per 100,000 and in women, prevalence rates vary from 164 (white) to 406 (African American) per 100,000.

Further, the report states that the major challenge is the unawareness of lupus among the population. According to the Lupus Foundation of America, at least 1.5 million Americans are living with diagnosed lupus. The foundation believes that the number of people who actually have the condition is much higher and that many cases go undiagnosed. Exact cause of SLE is still not known but several factors have been associated with the disease like genetics, environment and sex & hormones.

Based on geography, GSK receives FDA approval for a new self-injectable formulation of Benlysta (belimumab) for systemic lupus erythematosus in Europe and US recently; therefore Europe tends to be the dominating market in global self-injectable belimumab market in 2017. However, estimated incidence rates are 1 to 25 per 100,000 in North America, South America, Europe, and Asia and disease appears to be more common in urban than rural areas. In the United States, the prevalence of SLE is higher among Asians, African Americans, African Caribbean, and Hispanic Americans compared with Caucasians while in European countries, the prevalence of SLE is also higher among people of Asian and African descent hence, by comparison SLE occurs infrequently in Africa. In New Zealand, the prevalence and mortality of SLE are higher in Polynesians than Caucasians.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

For a full detailed overview, send us the sample request.

Key questions answered in this Self-injectable Belimumab Market report

  • What is the total market size by 2024 and what would be the expected growth rate of sales?
  • What is the revenue of Self-injectable Belimumab in 2015-16 and what would be the expected demand over the forecast period?
  • What are the key market trends?
  • What are the factors which are driving this market?
  • What are the major barriers to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities for the existing and entry level players?
  • What are the recent developments and business strategy of the key players?

We can provide two hour complimentary interaction with our analyst after the purchase of this market report. Details are imparted within the report.


A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements


Global Self-Injectable Belimumab Market by Mode of Injection (Subcutaneous Autoinjector, Subcutaneous Prefilled Syringe, & Intravenous Infusion), by Geography, and Market Opportunity Assessment With Forecast 2016-2024

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

OR Call Us:+1-646-568-7747

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements